News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase III
Cardiorentis Completes Enrollment In Pivotal Phase III Clinical Trial Of Ularitide For Acute Heart Failure 5/22/2015
Johnson & Johnson (JNJ) Announced 10 New Approval Applications with $1 Billion Revenue Potential Each 5/21/2015
Analysts Question Intercept Pharma (ICPT) NASH Trial Phase III Length and Size 5/21/2015
IntelliPharmaCeutics Intends To Accelerate Its Rexista(TM) Oxycodone XR Development Program On The Basis Of Positive Feedback From The FDA 5/21/2015
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Study Demonstrates Significant Burden Of Obesity On Patients' Recovery From Acute Bacterial Skin Infections 5/20/2015
Bristol-Myers Squibb (BMY) Receives Amended FDA Breakthrough Therapy Designation For Investigational Daclatasvir-Based Hepatitis C Regimen 5/20/2015
Boehringer Ingelheim Release: New Data Show Benefit Of Tiotropium/Olodaterol Respimat From The Start Of COPD Maintenance Therapy1,2,3 5/20/2015
Boehringer Ingelheim Release: New Data Analyses On Investigational Tiotropium/Olodaterol Respimat Showed Greater Lung Function Improvement Compared To Tiotropium And Olodaterol Alone 5/20/2015
Alnylam (ALNY) Receives Orphan Drug Designation From The United States FDAFor Revusiran, An Investigational Rnai Therapeutic For The Treatment Of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) 5/20/2015
Sunovion Pharmaceuticals Inc. Announces Positive Results for Latuda(Lurasidone HCL) In First Placebo-Controlled Trial Of Patients With Major Depressive Disorder With Mixed (Subsyndromal Hypomanic) Features 5/20/2015
Novartis AG (NVS) Reports Two Positive U.S. Phase III Programs in COPD 5/20/2015
Eleven Biotherapeutics (EBIO) Stock Nosedives 80% Premarket as Eye Drug Flunks Phase III Test 5/19/2015
Debiopharm Announces Phase III Positive Results For Triptorelin 6-Month Formulation In The Management Of Central Precocious Puberty (CPP) 5/19/2015
vTv Therapeutics Initiates Pivotal Phase 3 Trial Evaluating Azeliragon For The Treatment Of Patients With Mild Alzheimer's Disease 5/19/2015
Cempra Pharmaceuticals, Inc. (CEMP) Presenting Additional Data From The Phase III Oral Solithromycin Study In Community Acquired Bacterial Pneumonia At The American Thoracic Society Conference 5/19/2015
Corium International, Inc. Announces Publication Of Promising Data For Needle-Free Transdermal Influenza Vaccine 5/19/2015
pSivida (PSDV) Reports Positive IOP Safety Data In Phase III Trial Of Medidur For Posterior Uveitis 5/19/2015
Janssen Pharmaceuticals, Inc. Release: U.S. FDA Approves INVEGA TRINZA, First and Only Four-Times-A-Year Treatment For Schizophrenia 5/19/2015
Analysis Of Phase II Data For Celgene (CELG)’s Investigational Oral GED-0301 In Patients With Active Crohn’s Disease Presented At Digestive Disease Week 5/19/2015
Janssen Enters Into A Worldwide Collaboration With Achillion (ACHN) To Combat Hepatitis C Virus 5/19/2015
XBiotech USA (XBIT) Secures Approval From Data Safety Monitoring Board To Continue Phase III Registration Study In Europe For Its Novel Cancer Immunotherapy 5/18/2015
TissueGene, Inc. Announces Special Protocol Assessment (SPA) Agreement With The FDA For Its Phase 3 Clinical Trial Of Invossa For Patients Suffering From Osteoarthritis Of The Knee 5/18/2015
Astellas Pharma US Release: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial 5/18/2015
Janssen Pharmaceuticals, Inc. Release: New Real-World Data Show Adults with Type 2 Diabetes, Including Those Taking Multiple Diabetes Medications, Achieve Blood Glucose Treatment Goals After Using INVOKANA (canagliflozin) 5/18/2015
Boehringer Ingelheim Presents New Data And Analyses Reinforcing The Safety And Efficacy Of OFEV (nintedanib) Capsules 5/18/2015
RedHill Biopharma Ltd. (RDHL)'s Investor Webcast Forum Provides Update On The RHB-105 Phase III Program And Potential H. Pylori Eradication Market 5/18/2015
Eleven Biotherapeutics (EBIO) Announces Top-Line Results From Pivotal Phase 3 Study Of EBI-005 In Patients With Moderate To Severe Dry Eye Disease 5/18/2015
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2015 Financial Results And Provides Corporate Update 5/18/2015
Celgene (CELG) Release: FDA Fast Track Designation Granted To Luspatercept For The Treatment Of Patients With Beta-Thalassemia 5/18/2015
Vertex (VRTX) Release: The New England Journal of Medicine Publishes Data From Two Phase 3 Studies Of ORKAMBITM (Lumacaftor/Ivacaftor) In People With Cystic Fibrosis Who Have Two Copies Of The F508del Mutation 5/18/2015
Daiichi Sankyo Release: MOVANTIK (naloxegol) Safety Analyses Of Opioid-Induced Constipation Patients 65 And Older With Chronic Non-Cancer Pain 5/18/2015
University of Washington Release: Results From The First New Therapeutic Trials In Primary Biliary Cirrhosis (PBC) In A Decade To Be Presented At Digestive Disease Week (DDW) 5/18/2015
Puma Biotech (PBYI) Founder Loses $250 Million on Disappointing Breast Cancer Drug Data 5/15/2015
AbbVie (ABBV), Bristol-Myers Squibb (BMY) Drug Delays Blood Cancer Progression 5/15/2015
Janssen Pharmaceuticals, Inc. Release: Real-World Data Presented At American Geriatrics Society Meeting Show Consistent Safety Of XARELTO In Elderly Patients 5/15/2015
Endo Pharmaceuticals (ENDP) And BioDelivery Sciences International (BDSI) Present Pivotal Data From Two Phase 3 Trials Demonstrating Safety And Efficacy Of Buprenorphine Hcl Buccal Film For The Management Of Chronic Pain 5/15/2015
Janssen Pharmaceuticals, Inc. Release: New Data On XARELTO Versus Vitamin K Antagonists In Atrial Fibrillation Patients Undergoing Catheter Ablation Presented At Heart Rhythm 2015 5/15/2015
Innocoll, Inc. (INNL) Announces First Patient Dosed In The Cogenzia COACT-1 Phase III Study For The Treatment Of Diabetic Foot Infection 5/15/2015
Angionetics Presents at the 2015 American Society Of Gene & Cell Therapy Conference On Generx Angiogenic Phase 3 Gene Therapy Program 5/15/2015
Novo Nordisk Inc. Release: New Analysis Of Data In Adults With Obesity Or Who Are Overweight With Weight-Related Comorbidities Showed Early Response To Saxenda (liraglutide [rDNA origin] injection) Predicted Greater Weight Loss 5/15/2015
ResMed (RMD) Heart Trial Stopped After Putting Patients at Risk 5/14/2015
Argos Therapeutics, Inc. (ARGS) Provides Update On Enrollment Progress For Ongoing Pivotal Phase III ADAPT Clinical Trial 5/14/2015
Angion Biomedica Corp. Advances BB3 Into Pivotal Phase 3 Clinical Trial In Renal Transplant Patients With Delayed Graft Function 5/14/2015
NewLink Genetics (NLNK) Plunges Premarket as Pancreatic Cancer Vaccine Still Sees 75% Mortality Rate 5/13/2015
TONIX Pharmaceuticals, Inc. (TNXP) Launches Phase III Clinical Study Of TNX-102 SL In Fibromyalgia 5/13/2015
CEL-SCI (CVM) Receives Authorization To Conduct Its Phase 3 Multikine Trial In Italy 5/13/2015
Bavarian Nordic (BAVA.CO) Announces Positive Results From Two Pivotal Clinical Studies Of IMVAMUNE Smallpox Vaccine 5/13/2015
Pain Therapeutics (PTIE) Announces Positive Top-Line Results From Human Abuse Potential Study With REMOXY 5/12/2015
Merck KGaA (MKGAF.PK), Darmstadt, Germany, Receives FDA Fast Track Designation For Evofosfamide For The Treatment Of Patients Living With Advanced Pancreatic Cancer 5/12/2015
NewLink Genetics (NLNK)' IMPRESS Phase III Pancreatic Cancer Trial With Algenpantucel-L To Continue Following Second Interim Analysis 5/12/2015
Takeda (TKPYY) Announces First Patient Enrolled In Global Phase 3 Study Of Ixazomib As Maintenance Therapy For Newly Diagnosed Multiple Myeloma 5/12/2015
Ophthotech Corporation (OPHT) Completes Patient Recruitment Of The First Phase 3 Pivotal Trial Of Fovista Anti-PDGF Therapy In Combination With Lucentis In Wet Age-Related Macular Degeneration Program 5/12/2015
Threshold Pharmaceuticals, Inc. (THLD)' Partner Merck KGaA (MKGAF.PK), Darmstadt, Germany, Receives FDA Fast Track Designation For Evofosfamide For The Treatment Of Patients Living With Advanced Pancreatic Cancer 5/12/2015
Results From Pulmonary Non-Tuberculous Mycobacteria (PNTM) Study Using Aradigm Corporation (ARDM)’s Liposomal Ciprofloxacin To Be Presented At American Thoracic Society 2015 International Conference 5/12/2015
CureMark, Launches New Phase III Trial In Expanded Population Of Children With Autism 5/11/2015
Chiasma Announces New Data For Investigational Octreotide Capsules To Be Presented At ECE 2015 5/11/2015
GenSpera Provides Corporate Update 5/11/2015
GW Pharma (GWPH) Initiates Phase 3 Pivotal Study Of Epidiolex (CBD) In Lennox-Gastaut Syndrome 5/11/2015
Lipocine Inc. (LPCN) Announces Presentation Of Additional LPCN 1021 Clinical Data At American Urological Association Annual Meeting 5/11/2015
CEL-SCI (CVM) Receives Authorization To Conduct Its Phase 3 Multikine Trial In Spain 5/11/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: Researchers Report That Long-Term Administration Of Thymosin B4 In A Diabetic Animal Model Prevents Progression Of Peripheral Neuropathy And Restores Sciatic Nerve Function 5/8/2015
RedHill Biopharma Ltd. (RDHL) To Host Investor Webcast Forum Following Completion Of RHB-105 Dosing In Phase III Study 5/7/2015
SANUWAVE, Inc. Provides An Update On The Dermapace Clinical Trial 5/7/2015
ViiV Healthcare Begins Phase III Programme With dolutegravir/rilpivirine Combination For HIV Maintenance Therapy 5/6/2015
AbbVie (ABBV) Release: Investigational Medicine Venetoclax Receives Breakthrough Therapy Designation In Relapsed Or Refractory Chronic Lymphocytic Leukemia In Previously Treated Patients With The 17p Deletion Genetic Mutation 5/6/2015
Indivior PLC Announces Positive Top-Line Results From Pivotal Phase 3 Trial Of RBP-7000 In Schizophrenia 5/5/2015
Oxford BioMedica PLC (OXB.L) Announces That A Summary Of The 12 Month And Three Year Follow Up Data From The Phase I/II Study With Prosavin Was Presented At The AANS Conference In The U.S. 5/5/2015
AbbVie (ABBV) Announces Pivotal Phase 3 Data Evaluating Efficacy And Safety Of HUMIRA (Adalimumab) In Patients With Non-Infectious Intermediate, Posterior, Or Panuveitis 5/5/2015
Tocagen Inc. Presents Updated Interim Survival Data From Ongoing Clinical Studies At American Association Of Neurological Surgeons (AANS)/Congress Of Neurological Surgeons (CNS) Section On Tumors 5/4/2015
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus XR Demonstrates Improved Pharmacokinetic Profile In African-American Transplant Recipients 5/4/2015
CytoDyn Submits Phase 3 Protocol To FDA After Agreement On Protocol Synopsis 5/4/2015
Braeburn Pharmaceutical Expands Pipeline To Include Schizophrenia With Endo Pharmaceuticals (ENDP) Deal 5/1/2015
Tesaro, Inc. (TSRO) Announces Completion Of Targeted Enrollment In Phase III NOVA Trial And Initiation Of The QUADRA Trial Of Niraparib 5/1/2015
CEL-SCI (CVM) Reports 4th Consecutive Month Of Record Patient Enrollment In 2015 For Its Phase III Head And Neck Cancer Trial 5/1/2015
Celgene (CELG) Release: Analysis Of REVLIMID (Lenalidomide) In Patients With Non-Del-5Q MDS Demonstrated Improved Health Related Quality Of Life Measures 5/1/2015
NeoStem, Inc. Announces First Patient Randomized In Pivotal Phase III Melanoma Immunotherapy Clinical Trial 4/30/2015
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Custirsen Phase 3 "ENSPIRIT Trial Update 4/30/2015
Lexicon Pharmaceuticals, Inc. (LXRX) Provides Clinical Pipeline Update And Reports 2015 First Quarter Financial Results 4/30/2015
Lipocine Inc. (LPCN) Announces Completion Of LPCN 1021, Oral Testosterone, Phase III Clinical Trial 4/30/2015
Celgene (CELG) And Acceleron Pharma Select Luspatercept To Advance To Phase 3 In Myelodysplastic Syndromes 4/30/2015
Gilead (GILD), Achillion (ACHN) Race to Grab Market Share As HCV Populations Abound 4/29/2015
AstraZeneca PLC (AZN) Release: Selumetinib Granted Orphan Drug Designation By FDA 4/29/2015
ErgoMed’s Co-Development Partner AEterna Zentaris (AEZS) Obtains Positive Recommendation From Data Safety Monitoring Board 4/29/2015
Amgen (AMGN) Announces FDA Advisory Committee Meeting To Review Repatha (Evolocumab) As A Treatment For High Cholesterol 4/29/2015
XBiotech USA (XBIT) Enrolls First Patient Under Revised Protocol For U.S. Phase III Registration Study Using Xilonix For Treatment Of Metastatic Colorectal Cancer 4/29/2015
GlaxoSmithKline (GSK)'s Shingles Vaccine 97.2% Effective 4/28/2015
CoLucid Pharma Announces Initiation Of First Phase 3 Pivotal Trial Of Lasmiditan In Migraine 4/28/2015
AEterna Zentaris (AEZS): Data Safety Monitoring Board Recommends Continuation Of Phase 3 Study Of Zoptarelin Doxorubicin In Advanced Endometrial Cancer 4/28/2015
Synthon Pharmaceuticals Announces Successful Outcomes From The Open-Label Extension Of The Phase III GATE Study Of Synthon’s Glatiramer Acetate 4/28/2015
Merck & Co. (MRK) Announces Publication Of Pivotal Data From Phase 3 Clinical Studies Of ZERBAXA (Ceftolozane/Tazobactam) In The Lancet And Clinical Infectious Diseases 4/28/2015
Aerie (AERI) Freefalls Aftermarket as Rhopressa Fails Phase III Study 4/27/2015
TetraPhase Pharmaceuticals (TTPH)'s Eravacycline Meets Primary Endpoint In Phase III Study 4/27/2015
AbbVie (ABBV) Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX + EXVIERA In Chronic Hepatitis C Patients With Renal Impairment At The International Liver Congress 2015 4/27/2015
Can-Fite BioPharma (CFBI) Reports Positive Results From Further Analysis Of Phase II/III Psoriasis Trial 4/27/2015
RedHill Biopharma Ltd. (RDHL) Announces Completion Of Patient Enrollment In A Phase III Study Of RHB-105 For H. Pylori Infection 4/27/2015
NeoStem, Inc.'s Lead Immuno-Oncology Product Candidate, NBS20, Receives ATMP Classification From The European Medicines Agency 4/27/2015
Bristol-Myers Squibb (BMY) Release: ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% Of Post-Liver Transplant Patients With Hepatitis C And Up To 94% Of Hepatitis C Patients With Cirrhosis (Child-Pugh Class A Or B) 4/27/2015
Enanta Pharmaceuticals, Inc. Announces Preliminary Data From AbbVie (ABBV)’s Phase 3b RUBY-I Study In Chronic Hepatitis C Patients With Renal Impairment Presented At The International Liver Congress 2015 4/27/2015
Otonomy, Inc. (OTIC) Presents Auripro Phase III Results At American Society Of Pediatric Otolaryngology Conference 4/27/2015
BioMarin (BMRN) Presents Data On Duchenne Muscular Dystrophy At The 67th American Academy of Neurology Annual Meeting 4/24/2015
GlaxoSmithKline (GSK)'s Malaria Vaccine Phase III Study Containing Agenus’ QS-21 Published In The Lancet 4/24/2015
GENFIT (ALGFT): New Proof Of Efficacy Of Gft505 In Nash And Positive Expert Opinion 4/24/2015
Actavis (ACT) Announces Topline Phase 3 Clinical Trial Results For Single-Dose DALVANCE (Dalbavancin) In The Treatment Of ABSSSI 4/24/2015
Aerie (AERI) Reports Initial Rhopressa Phase III Efficacy Results 4/24/2015
MedDay Reports Positive Pivotal Phase III Study Results With MD1003 In Patients With Progressive Multiple Sclerosis 4/24/2015
Astellas Pharma US Release: CRESEMBA (Isavuconazonium Sulfate) Data To Be Presented At The European Congress Of Clinical Microbiology And Infectious Diseases 4/24/2015
BioTie Therapies Corp. Provides Update On Tozadenant Phase 3 Program 4/23/2015
Merck & Co. (MRK) Announces Results From Phase 2/3 Study Of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir In Patients With Advanced Chronic Kidney Disease 4/23/2015
Medivir AB (MVRBF): Data From OPTIMIST Trials Show SVR12 Rates Of 97 Percent In HCV Patients Without Cirrhosis And 84 Percent In HCV Patients With Cirrhosis 4/23/2015
Merck & Co. (MRK) Touts Results From C-SURFER Phase II/III Clinical Trial 4/23/2015
Effect Of Genzyme (GENZ)’s Multiple Sclerosis Treatment Lemtrada (Alemtuzumab) On Slowing Brain Atrophy And MRI Lesion Activity Maintained Through Four Years 4/23/2015
Janssen Sciences Ireland UC Announces SVR12 Rates With Twelve Weeks Of Treatment With All-Oral, Once-Daily Regimen Of Simeprevir ? Plus Sofosbuvir ? In Genotype 1 HCV Patients With And Without Cirrhosis 4/23/2015
GW Pharmaceuticals (GWPH) Announces New Physician Reports Of Epidiolex Treatment Effect In Children And Young Adults With Treatment-Resistant Epilepsy 4/23/2015
Isis Pharmaceuticals, Inc. (ISIS) Reports Positive Data From ISIS-TTR Rx In Patients With TTR Amyloidosis 4/23/2015
CorMedix (CRMD) Presents Data from Neutrolin Post Marketing Surveillance Study At Two Medical Conferences 4/23/2015
Janssen Announces SVR12 Rates With Twelve Weeks Of Treatment With All-Oral, Once-Daily Regimen Of Simeprevir Plus Sofosbuvir In Genotype 1 HCV Patients With And Without Cirrhosis 4/23/2015
Pfizer (PFE)'s New Leukemia Drug Meets Hematologic Remission Endpoint in Phase III Study 4/22/2015
Eli Lilly (LLY)'s Ixekizumab Succeeds in Late-Stage Study, Meets Primary Endpoint 4/22/2015
Portage Biotech's Biohaven To Begin Phase 1 Study In 3Q2015 And Readying For Phase 3 Study Start By 1Q2016 4/22/2015
Celator Pharmaceuticals, Inc. Presents Data At AACR Annual Meeting 4/22/2015
Baxter International (BAX)'s Bleeding Disorder Drug Delivers 100% Success Rate in Late-Stage Study 4/21/2015
GW Pharmaceuticals (GWPH) Initiates Second Phase 3 Pivotal Trial For Epidiolex In Dravet Syndrome 4/21/2015
Otonomy, Inc. (OTIC) To Present Auripro Phase 3 Results At American Society Of Pediatric Otolaryngology Conference 4/21/2015
Acacia Pharma Initiates Phase 3 Combination Prophylaxis Study With APD421 In Post-Operative Nausea & Vomiting (PONV) 4/21/2015
Biogen (BIIB) Release: PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented At American Academy of Neurology Annual Meeting Support Long-Term Safety And Efficacy In Multiple Sclerosis Patients 4/21/2015
Upsher-Smith Laboratories Research On Qudexy XR (topiramate) Extended-Release Capsules Highlighted At the 2015 American Academy of Neurology Annual Meeting 4/21/2015
Enrollment In Mast Therapeutics (MSTX)' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 4/21/2015
Onconova Therapeutics Inc. (ONTX) Highlights Rigosertib And Early-Stage Programs At The 2015 AACR Annual Meeting 4/21/2015
KEYTRUDA (Pembrolizumab), Merck & Co. (MRK)’s Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival And Overall Response Rate Compared To Ipilimumab An Anti-CTLA-4 Therapy 4/20/2015
Full Data On Baxter International (BAX)’s Investigational Recombinant Treatment BAX 111 Supports Potential Role To Treat Von Willebrand Disease 4/20/2015
Cyclacel Pharmaceuticals, Inc. (CYCC)'s Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential And Synergy With Other Anti-Cancer Compounds 4/20/2015
MediWound (MDWD) Initiates U.S. Phase 3 Trial With NexoBrid To Treat Severe Burns 4/20/2015
Argos Therapeutics, Inc. (ARGS) To Present Update On Pivotal Phase 3 ADAPT Clinical Trial During 2015 ASCO Annual Meeting 4/20/2015
SAGE Therapeutics Announces First Patient Treated Under Phase 3 Expanded Access Protocol To Evaluate SAGE-547 In Patients With Super-Refractory Status Epilepticus 4/20/2015
Onconova Therapeutics Inc. (ONTX) Submits Pivotal Clinical Trial Protocol For IV Rigosertib In Higher-Risk Myelodysplastic Syndromes To FDA And European Medicines Agency 4/20/2015
Data Presented At AACR Demonstrate Peregrine Pharmaceuticals, Inc. (PPHM)' Bavituximab Induces Immune Activation In PD-L1 Negative NSCLC Tumors 4/20/2015
Eli Lilly (LLY)'s Ixekizumab Met Primary Endpoint In A Phase 3 Study Investigating The Treatment Of Psoriatic Arthritis 4/20/2015
Pembrolizumab, Merck & Co. (MRK)'s Investigational Anti PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival And Overall Response Rate Compared To Ipilimumab, An Anti-CTLA-4 Therapy, In A Phase 3 Study Of Patients With Advanced Melanoma 4/20/2015
Merz Neurosciences To Present Key Clinical Data At The Annual Meeting Of The American Academy of Neurology 4/20/2015
Bio Products Laboratory, Ltd. Announces Results From Phase III Registration Study Of Its Factor X Coagulation Product 4/20/2015
Global Strategic Partners Merck KGaA (MKGAF.PK), Darmstadt, Germany, And Pfizer (PFE) nitiate Phase III Study With Avelumab* In Patients With Stage IIIb/IV Non-Small Cell Lung Cancer 4/20/2015
Ampio Pharmaceuticals, Inc. (AMPE) Shares Decimated on Failed Trial Results 4/20/2015
Bristol-Myers Squibb (BMY) Soars After Halting Study Early As Opdivo Aces Test Again 4/17/2015
Pfizer (PFE) Beams As Cancer Drug Efficacy Stops Trial Early and Analysts Predict Game Changer 4/17/2015
Investors Suddenly Interested in Synta (SNTA) and Its Upcoming Cancer Data 4/17/2015
Ipsen (IPN.PA), Active Biotech AB (BTPC) Plummet As Prostate Cancer Drug Flunks Late-Stage Trial 4/17/2015
H. Lundbeck A/S (LUN.CO) and Otsuka America Pharmaceutical, Inc. Release: Results Of Phase III Study Of Brexpiprazole In Adult Patients With Schizophrenia Published In American Journal Of Psychiatry 4/17/2015
MedDay Announces Its Pivotal Phase III Study Of MD1003 In Patients With Progressive Multiple Sclerosis Meets Primary Endpoint 4/17/2015
Full Data On Baxter International (BAX)’s Investigational Recombinant Treatment BAX 111 Supports Potential Role To Treat Von Willebrand Disease 4/17/2015
Galena Biopharma  (GALE) Completes Over-Enrollment Of Neuvax (Nelipepimut-S) Phase 3 PRESENT Clinical Trial 4/16/2015
ZS Pharma (ZSPH) Announces Publications In Peer-Reviewed Medical Journals 4/16/2015
Peregrine Pharmaceuticals, Inc. (PPHM) Announces Three Abstracts Accepted For Presentation At American Association for Cancer Research 2015 Annual Meeting 4/16/2015
AEterna Zentaris (AEZS) Files Additional Patent Application To Strengthen IP Protection Of Zoptarelin Doxorubicin 4/16/2015
Adamis (ADMP) Pharmaceuticals Announces Positive Clinical Study Results For Its Albuterol (Salbutamol) HFA Product 4/16/2015
RegeneRx JV Retains Ora, Inc. To Conduct Phase 3 Trial For NK And Phase 2b/3 Trial For Dry Eye Syndrome In U.S. 4/16/2015
AbbVie (ABBV)'s Investigational Chronic Hepatitis C Treatment Granted Priority Review In Japan 4/16/2015
TRANSGENE (ENX:TNG): Agreement With FDA Announced For Special Protocol Assessment For Upcoming Phase 3 Pexa-Vec Trial In Advanced Liver Cancer 4/16/2015
SillaJen Announces Agreement With The FDA For A Special Protocol Assessment For Upcoming Phase 3 Pexa-Vec Trial In Advanced Liver Cancer 4/16/2015
Provectus Biopharmaceuticals Inc. Opens Patient Enrollment; Begins Phase 3 International FDA Comparative Clinical Trial Of PV-10 For Melanoma 4/16/2015
Roche (RHHBY) Says 11 Late-Stage Cancer Drugs Will Enter Trials in 2015 4/15/2015
Pfizer (PFE) Announces Paloma-3 Trial For Ibrance® (Palbociclib) Stopped Early Due To Efficacy Seen In Patients With Hr+, Her2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy 4/15/2015
Ocular Therapeutix (OCUL) Stock Caves After Eye Pain Drug Flunks Pivotal Trial 4/15/2015
Phase III Trial Of The Merck & Co. (MRK) And NewLink Genetics Investigational Ebola Vaccine Initiated In Sierra Leone 4/15/2015
Heart Metabolics And FDA Reach Agreement On Special Protocol Assessment For Single Phase 3 Trial Of Perhexiline In Hypertrophic Cardiomyopathy 4/15/2015
Heart Metabolics Limited And FDA Reach Agreement On Special Protocol Assessment For Single Phase 3 Trial Of Perhexiline In Hypertrophic Cardiomyopathy 4/15/2015
CytoTools: Recruitment Of Patients Now Complete For European Studies On Diabetic Foot (DFU) And Ulcus Cruris (VLU) Indications 4/15/2015
Oncobiologics Inc. Announces Completion Of Clinical Dosing For bevacizumab (Avastin biosimilar) Candidate 4/15/2015
Bayer HealthCare (BAY) Devises Phase III Plans for Top Prospect 4/14/2015
Soligenix (SNGX) Announces FDA Protocol Clearance Of Pivotal Phase 3 Clinical Trial Of SGX203 In Pediatric Crohn's Disease 4/14/2015
Catalyst Pharmaceuticals (CPRX) Announces Oral Presentation Of Firdapse Phase 3 Trial Data At American Academy of Neurology Annual Meeting (AAN) 4/14/2015
DBV Tech Nabs FDA Breakthrough Status for Peanut Allergy Patch 4/13/2015
AEterna Zentaris (AEZS) Announces Plans To Initiate Phase 3 Study Of Macrilen In AGHD Following Successful Meeting With FDA 4/13/2015
Angionetics Initial Equity Funding To Advance As Independent Company To Develop And Commercialize Phase 3 Generx Gene Therapy Product Candidate 4/13/2015
Neothetics Initiates Pivotal Phase 3 Clinical Trials For LIPO-202, The First Non-Invasive Injectable Drug Candidate For Reduction Of Subcutaneous Abdominal Fat 4/13/2015
UK’s Aintree University Hospital Joins CEL-SCI (CVM)’s Phase III Head And Neck Cancer Trial 4/13/2015
Onxeo Announces 6th Positive DSMB Recommendation For Livatag Relive Study In HCC 4/13/2015
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Shows That Health-Related Quality-Of-Life Is Higher In ABSSSI Patients Deemed Cured Vs Improved After End Of Treatment 4/10/2015
Cesca Therapeutics Management Provides Update On Clinical Trials For Critical Limb Ischemia ("CLI") And Acute Myocardial Infarction ("AMI") 4/10/2015
Adamas Pharmaceuticals (ADMS) Receives Orphan Drug Designation For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia Associated With Parkinson's Disease 4/10/2015
Lipocine Inc. (LPCN) Announces Presentation Of Additional LPCN 1021 Clinical Data At American Society Of Andrology 40th Annual Conference 4/10/2015
Horizon Pharma (HZNP) Receives FDA Fast Track Designation For ACTIMMUNE In The Treatment Of Friedreich's Ataxia 4/10/2015
BioLife Solutions, Inc. (BLFS.OB) CryoStor Cell Preservation Media Embedded In Cardio3 BioSciences' Phase III Clinical Trials Of C-Cure Cell Therapy For Congestive Heart Failure 4/9/2015
Exelixis, Inc. (EXEL)’s Cabozantinib Granted Fast Track Designation By FDA For Advanced Renal Cell Carcinoma 4/9/2015
Edge Therapeutics Banks $72.5 Million for Phase III Brain Hemorrhage Study 4/9/2015
Mesoblast Limited (MSB.AX) Phase 3 Program For Degenerative Disc Disease To Include European Sites After Positive Meeting With European Medicines Agency 4/8/2015
Portola Pharmaceuticals, Inc. Announces New Topline Data From Phase III Annexa-A Trial Part 2: Breakthrough Designated Andexanet Alfa 4/8/2015
GlycoMimetics, Inc. (GLYC) Provides Update On Pfizer (PFE)’s Plans To Initiate Phase 3 Trial With Rivipansel In Mid-2015 4/7/2015
Ocular Therapeutix (OCUL) Reports Topline Clinical Data For Its Second Phase 3 Clinical Trial Evaluating OTX-DP For The Treatment Of Post-Surgical Ocular Inflammation And Pain 4/7/2015
Taxus Cardium (CRXM) Announces Agreement With Dr. Reddy's Laboratories Ltd. (RDY) To Co-Develop, Market & Sell Generx Angiogenic Microvascular Gene Therapy In Certain International Markets 4/7/2015
MedDay Provides Update On Pioneering Pivotal Phase III Study Design In Progressive Multiple Sclerosis 4/7/2015
Cytori Therapeutics, Inc. (CYTX) Granted Orphan Drug Status For Cellular Therapeutic In European Union 4/7/2015
Charleston Laboratories, Inc. Completes Patient Enrollment In A Phase 3 Study Of Lead Product, CL-108 4/6/2015
Icon Bioscience Reports Successful Outcomes Of Phase 3 Study Of IBI-10090, A Novel Sustained Release Drug Being Developed To Treat Inflammation Associated With Cataract Surgery 4/6/2015
Flexion (FLXN) CEO Discusses Pipeline and Jobs 4/3/2015
Public Health Agency of Canada Release: Clinical Trials Prove Canada's VSV-EBOV Ebola Vaccine Safe And Effective 4/2/2015
Heron Therapeutics, Inc. (APPA) Reaches Target Patient Enrollment In MAGIC Phase 3 Study Of SUSTOL 4/2/2015
Thrasos Scores $21M to Complete Phase II THR-184, Expands Renal Portfolio 4/1/2015
Kala Pharmaceuticals KPI-121 Meets All Primary Endpoints In Phase III For Cataract Surgery 4/1/2015
Pivotal Pharmacokinetic Study Of Innocoll, Inc. (INNL)'s Xaracoll(R) Supports Use Of 300 Mg Dose For Phase 3 Clinical Studies In Post-Operative Pain 4/1/2015
Receptos (RCPT) Completes Enrollment Of RADIANCE Phase 3 Trial Of Ozanimod In Relapsing Multiple Sclerosis 4/1/2015